Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 166

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes

Open access
Biftu, Tesfaye, Sinha-Roy, Ranabir, Chen, Ping, Qian, Xiaoxia, Feng, Dennis, Kuethe, Jeffrey T., Scapin, Giovanna, Gao, Ying Duo, Yan, Youwei, Krueger, Davida, Bak, Annette, Eiermann, George, He, Jiafang, Cox, Jason, Hicks, Jacqueline, Lyons, Kathy, He, Huaibing, Salituro, Gino, Tong, Sharon, Patel, Sangita, Doss, George, Petrov, Aleksandr, Wu, Joseph, Xu, Shiyao Sherrie, Sewall, Charles, Zhang, Xiaoping, Zhang, Bei, Thornberry, Nancy A., Weber, Ann E. · 2014 · Journal of Medicinal Chemistry

Abstract

In our effort to discover DPP-4 inhibitors with added benefits over currently commercially available DPP-4 inhibitors, MK-3102 (omarigliptin), was identified as a potent and selective dipeptidyl peptidase 4 (DPP-4) inhibitor with an excellent pharmacokinetic profile amenable for once-weekly human dosing and selected as a clinical development candidate. This manuscript summarizes the mechanism of action, scientific rationale, medicinal chemistry, pharmacokinetic properties, and human efficacy data for omarigliptin, which is currently in phase 3 clinical development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/jm401992e

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 166

Metadata

Authors
Biftu, T., Sinha-Roy, R., Chen, P., Qian, X., Feng, D., Kuethe, J. T., Scapin, G., Gao, Y. D., Yan, Y., Krueger, D., Bak, A., Eiermann, G., He, J., Cox, J., Hicks, J., Lyons, K., He, H., Salituro, G., Tong, S., Patel, S., Doss, G., Petrov, A., Wu, J., Xu, S. S., Sewall, C., Zhang, X., Zhang, B., Thornberry, N. A., & Weber, A. E.
Venue
Journal of Medicinal Chemistry
Published
2014-04-02
Volume
57
Issue
8
Pages
3205-3212
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2151185776
Cited by
166
References
1
FWCI
17.23
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes. https://app.cochat.ai/papers/10.1021/jm401992e
The paper
Biftu, T., Sinha-Roy, R., Chen, P., Qian, X., Feng, D., Kuethe, J. T., Scapin, G., Gao, Y. D., Yan, Y., Krueger, D., Bak, A., Eiermann, G., He, J., Cox, J., Hicks, J., Lyons, K., He, H., Salituro, G., Tong, S., . . . Weber, A. E. (2014). Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes. Journal of Medicinal Chemistry. https://doi.org/10.1021/jm401992e

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.